EXAS

53.07

0.72% 0.37

Handel nachbörslich: 53.07

Exact Sciences Corp (EXAS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$52.70

Offen:

$52.77

24-Stunden-Volumen:

2.49M

Relative Volume:

0.98

Marktkapitalisierung:

$9.87B

Einnahmen:

$2.69B

Nettoeinkommen (Verlust:

$-214.04M

KGV:

-33.47

EPS:

-1.5857

Netto-Cashflow:

$98.43M

1W Leistung:

+4.22%

1M Leistung:

-23.60%

6M Leistung:

-0.82%

1J Leistung:

-18.51%

1-Tages-Spanne:

$52.17

$54.06

1-Wochen-Bereich:

$48.72

$54.55

52-Wochen-Spanne:

$40.62

$79.62

Exact Sciences Corp Stock (EXAS) Company Profile

Firmenname

Exact Sciences Corp

Sektor

Healthcare (1196)

Branche

Diagnostics & Research (57)

Telefon

608-284-5700

Adresse

5505 ENDEAVOR LANE, MADISON, WI

Mitarbeiter

6,600

Twitter

@exactsciences

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

EXAS's Discussions on Twitter

Vergleichen Sie EXAS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EXAS	53.07	9.87B	2.69B	-214.04M	98.43M	-1.5857
TMO	516.10	196.16B	42.37B	6.14B	7.78B	15.26
DHR	235.09	167.14B	23.74B	3.89B	4.98B	7.93
A	132.05	37.71B	6.50B	1.41B	1.42B	3.82
IQV	197.53	35.48B	15.32B	1.41B	1.96B	5.95
IDXX	418.55	33.75B	3.84B	866.24M	792.60M	9.80

Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-08-28	Eingeleitet	Wells Fargo	Overweight
2024-06-27	Eingeleitet	Scotiabank	Sector Outperform
2024-06-03	Fortgesetzt	Jefferies	Buy
2024-01-02	Hochstufung	The Benchmark Company	Hold → Buy
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-10-10	Hochstufung	Piper Sandler	Neutral → Overweight
2023-09-28	Eingeleitet	Bernstein	Outperform
2023-08-02	Herabstufung	The Benchmark Company	Buy → Hold
2023-05-10	Hochstufung	Craig Hallum	Hold → Buy
2023-05-05	Eingeleitet	UBS	Neutral
2023-03-09	Hochstufung	Citigroup	Neutral → Buy
2023-02-10	Herabstufung	Credit Suisse	Outperform → Neutral
2023-01-18	Herabstufung	Raymond James	Outperform → Mkt Perform
2022-10-19	Herabstufung	Craig Hallum	Buy → Hold
2022-08-25	Eingeleitet	Credit Suisse	Outperform
2022-06-03	Eingeleitet	Piper Sandler	Neutral
2021-11-03	Herabstufung	Raymond James	Strong Buy → Outperform
2021-07-29	Bestätigt	BTIG Research	Buy
2021-07-29	Bestätigt	Canaccord Genuity	Buy
2021-07-29	Bestätigt	Oppenheimer	Outperform
2021-07-29	Bestätigt	Stifel	Buy
2021-06-15	Eingeleitet	Raymond James	Strong Buy
2021-06-03	Eingeleitet	Goldman	Buy
2021-05-25	Eingeleitet	Wells Fargo	Equal Weight
2021-01-28	Eingeleitet	Truist	Buy
2020-10-29	Herabstufung	UBS	Buy → Neutral
2020-10-28	Herabstufung	Citigroup	Buy → Neutral
2020-10-08	Fortgesetzt	BTIG Research	Buy
2020-04-02	Eingeleitet	Evercore ISI	Outperform
2020-01-10	Fortgesetzt	BTIG Research	Buy
2020-01-07	Eingeleitet	Citigroup	Buy
2019-12-13	Eingeleitet	Dougherty & Company	Buy
2019-11-15	Eingeleitet	Stifel	Buy
2019-10-17	Bestätigt	BofA/Merrill	Buy
2019-10-01	Fortgesetzt	Craig Hallum	Buy
2019-09-26	Eingeleitet	Oppenheimer	Outperform
2019-02-26	Hochstufung	Goldman	Neutral → Buy
2018-10-09	Eingeleitet	UBS	Buy
2018-09-05	Fortgesetzt	The Benchmark Company	Hold
2018-08-13	Bestätigt	Canaccord Genuity	Buy
2018-04-03	Hochstufung	BTIG Research	Neutral → Buy
2018-01-29	Eingeleitet	Goldman	Neutral
2018-01-08	Bestätigt	The Benchmark Company	Buy
2017-11-13	Herabstufung	Robert W. Baird	Outperform → Neutral
2017-11-01	Herabstufung	BTIG Research	Buy → Neutral

Alle ansehen

Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten

04:09 AM

Swiss National Bank Increases Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

04:09 AM

Nov 20, 2024

Madison-based Exact Sciences reports Q3 results short of analysts’ expectations - Chippewa Herald

Nov 20, 2024

EULAV Asset Management Has $20.78 Million Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Nov 20, 2024

Nov 19, 2024

Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right Now - Insider Monkey

Nov 19, 2024

Exact Sciences Co. (NASDAQ:EXAS) Sees Large Drop in Short Interest - MarketBeat

Nov 19, 2024

Exact Sciences Co. (NASDAQ:EXAS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Nov 19, 2024

Nov 18, 2024

Exact Sciences Partners with Actor and TV Personality Carlos Ponce to Increase Awareness of Colon Cancer Screening Among Hispanic Community - Business Wire

Nov 18, 2024

EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test - Yahoo Finance

Nov 18, 2024

Nov 16, 2024

Chairman of The Board & CEO of Exact Sciences Picks Up 2.7% More Stock - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Simplify Asset Management Inc. - MarketBeat

Nov 15, 2024

Exact Sciences showcases early cancer detection test data at AACR meeting - Clinical Trials Arena

Nov 15, 2024

Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat

Nov 15, 2024

Nov 14, 2024

Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy - BioSpace

Nov 14, 2024

Nov 13, 2024

Capital World Investors Reduces Stake in Exact Sciences Corp - GuruFocus.com

Nov 13, 2024

Exact Sciences CEO Kevin Conroy buys $1 million in stock By Investing.com - Investing.com Nigeria

Nov 13, 2024

Exact Sciences reports progress in early cancer detection - Investing.com

Nov 13, 2024

Exact Sciences reports progress in early cancer detection By Investing.com - Investing.com UK

Nov 13, 2024

Exact Sciences CEO Kevin Conroy buys $1 million in stock - Investing.com India

Nov 13, 2024

Exact Sciences' Cancer Test Shows 28% Better Early Detection, Could Cut Deaths by 17% | EXAS Stock News - StockTitan

Nov 13, 2024

Los Angeles Capital Management LLC Takes Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Nov 13, 2024

Nov 12, 2024